Thrombotic microangiopathy is a serious complication of hematopoietic stem cell transplant (HSCT). The etiology and pathogenesis of transplant-associated thrombotic microangiopathy (TA-TMA) following allogeneic HSCT appear to be quite different from that in cases seen after autologous HSCT. 1 Calcineurin inhibitors are often the culprit in the setting of allogeneic HSCT. The involved mechanisms may be different in cases seen early after transplant from those occurring later. In fact, TA-TMA is very rare after autologous HSCT. One published series reported a few children with neuroblastoma and TMA after autologous HSCT. 2 A 4-year-old Caucasian boy with high-risk neuroblastoma [left adrenal primary, stage IV (bone and bone marrow involvement), unfavorable histology, N-myc non-amplified] received induction chemotherapy per Children's Oncology Group (COG) protocol ANBL12P1 followed by tandem autologous HSCT and radiotherapy to the primary site per COG ANBL0532 protocol. Preparative regimens were cyclophosphamide/thiotepa for the first HSCT and carboplatin/etoposide/melphalan for the second. A nucleated cell dose of 11.2 × 10 8 /kg was infused with each HSCT. Tumor resection, which included left radical nephrectomy, occurred after the 4th cycle of chemotherapy.
He developed severe hypertension, proteinuria, hematuria and azotemia on day 12 of radiotherapy, and 70 days following second HSCT. Urinalysis showed 3+ blood and 3+ protein; microscopy revealed more than 100 RBC per high power field (h.p.f.). A spot urine for protein:creatinine (P:C) ratio (mg/mg) was markedly elevated at 12 (normal o 0.20). Bone marrow recovery was still ongoing at the time; hemoglobin and platelet count had declined slightly as had WBC count. Haptoglobin was low, and LDH was mildly elevated at 250-350 U/L with a peak of 458 (upper limit of normal 240 U/L), although not significantly different from previous values. Creatinine rose from 0.4-0.5 mg/dL to 0.7 mg/dL. Peripheral smear was reviewed repeatedly over several days, and no schistocytes were seen. Complement factor 3, 4, CH50 and ADAMTS13 were all within normal limits.
Serum IgG level was elevated after HSCT, including prior to initiation of local radiotherapy, and peaked at 3750 mg/dL (463-1447) 10 days prior to acute change in renal function. IgG subclass testing showed that the great majority of the IgG was IgG 1 subclass (3521 mg/dL). Furthermore, serum electrophoresis showed M spike of 1.64 g/dL, which constituted 21.3% of the plasma protein content. Immunofixation showed presence of an IgG kappa band. Urine protein electrophoresis showed 8.7 mg/dL and 34.3 mg/dL, corresponding to Bence Jones, kappa and IgG kappa bands on immunofixation, respectively. Serum IgG had also previously been elevated after first HSCT, but transiently, and to a much lesser degree, with maximum level of 1790 mg/dL. At the time, there were no other clinical findings, and it resolved spontaneously. Protein electrophoresis and immunofixation were not performed at that time.
Blood pressure was controlled on amlodipine, atenolol and minoxidil. There was stabilization of his blood pressure and some improvement in creatinine (peaked at 1.17 mg/dL). However, after 2 weeks of supportive therapy, and insignificant improvement in his renal function and urinary abnormalities, a renal biopsy was performed. The biopsy showed severe diffuse glomerular thrombotic microangiopathic lesion (TMA), with early scarring present in some of the glomeruli. Specifically, many glomeruli showed mesangiolysis with loss of nuclei in the mesangial tuft, as well as obliteration of the glomerular capillary loops. Fibrin was present along with schistocytes. Splitting and reduplication of basement membranes was seen in several glomeruli. Some glomeruli showed diffuse early scarring in the mesangium. An occasional glomerulus showed 2+ C3 deposition.
Thereafter, he received fresh frozen plasma (FFP) transfusions daily for 5 days, then 3 days a week, for 10 days total, without significant change in the clinical parameters of hypertension, renal function, or proteinuria. Terminal complement component C5 was elevated and complement factors B, H and I were within normal limits. Consequently, he was started on eculizumab, and thereafter all findings improved. He received induction with weekly infusions of eculizumab, 600 mg, based on weight. After 4 doses, hematologic findings improved, and he subsequently received 300 mg every other week. Creatinine improved significantly after the second dose, approximately 10 days after initiation, and is now near baseline. Haptoglobin and LDH normalized 2-3 weeks later. Platelet count also began to rise at 10 days, and hemoglobin stabilized. Proteinuria began to improve after about 2 weeks, now with a urine P:C ratio of 0.7; hematuria is also improving, beginning at approximately 1 week following eculizumab therapynow with 2-5 RBC/h.p.f.. Hypertension also improved, beginning 5-6 weeks after starting eculizumab, and he is now receiving a single antihypertensive (Table 1) . IgG level steadily declined since initiation of eculizumab, now normal at 933 mg/dL (Figure 1 ). Repeat serum immunofixation shows a faint IgG kappa band, measuring at most 0.4 g/dL. He received eight total doses of Bone Marrow Transplantation (2017) 52, 1662-1664 © 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 0268-3369/17 www.nature.com/bmt eculizumab. Four months have elapsed since eculizumab was discontinued, and TMA has not recurred.
TMA following autologous HSCT for the treatment of neuroblastoma has been reported in a recent series, and in all cases schistocytes were noted on the peripheral smear at some point. 2 Despite review on several occasions, schistocytes were never seen in our case, but, interestingly, were noted in the glomerular capillaries on renal biopsy. More recently, Jodele et al. 3 , in recommendations for new diagnostic criteria for TMA, reported that schistocytes in fact may not be present, although this represents a change in paradigm. Furthermore, the decline in hemoglobin and platelet count was modest in our case, particularly given the background of incomplete hematopoietic recovery at the time. The absence of schistocytes and rarity of TMA after autologous SCT may lead to a delay in diagnosis. Therefore, heightened physician awareness of TMA in these children, who may exclusively present with hypertension and renal dysfunction with hematuria and/or proteinuria, is critical.
TMA after autologous HSCT occurs rarely. In children, it has been reported following a preparative regimen of carboplatin/ etoposide/melphalan (CEM) for neuroblastoma, 4 as in our case. However, it most often occurred early after HSCT, and prior to radiation therapy. It is not known why it preferentially occurs in children with neuroblastoma. It is possibly related to the combination of medications used, and, in a minority, radiation therapy may play a role.
The increase in serum IgG appears to be unrelated to the conditioning regimen itself, as it occurred after both HSCT procedures. It may be speculated that the hypergammaglobulinemia was related to post-HSCT immune recovery, since serum IgG normalized after some time. However, immune globulin levels are generally normal after autologous HSCT, not elevated.
Furthermore, monoclonal gammopathy, particularly to the level observed in our patient, is almost unheard of at this young age.
In a review of serum immunofixation electrophoresis results in a pediatric population, monoclonal gammopathies observed included four HSCT recipients for solid organ malignancies; three of which existed prior to transplantation. Two cases were younger than 9 years of age, one younger than 3 years. The size of the M protein or other clinical features was not given in the report. 5 In adults, renal disease is very common in the setting of monoclonal gammopathies associated with plasma cell dyscrasias or lymphoproliferative disorders. However, TMA or atypical HUS is less common, and some of such cases were unresponsive to eculizumab. [6] [7] [8] [9] [10] To our knowledge, the association of TMA and monoclonal gammopathy following autologous HSCT has not been described in children. Possible mechanisms include monoclonal gammopathy leading to hyperviscosity and antibody production against unknown renal cellular targets. In this case, there was also a temporal association to radiation therapy, although the field did not include his solitary kidney. TMA has rarely been associated with radiation therapy, as well, 11 again in the adult population. It's role in the development of TMA may involve endothelial damage, although this is not clear.
The interesting aspects of this case are (1) the presence of significant hypergammaglobulinemia following autologous HSCT, with a sizeable M protein, at a very young age, associated with (2) TMA occurring after recent radiation exposure and (3) the absence of schistocytes on peripheral blood smear. Improvement in hypergammaglobulinemia and M protein coincided with the resolution of renal disease after eculizumab therapy. There was also a temporal association with radiation therapy, as there was no evidence of laboratory changes or hypertension prior to that, despite elevated serum IgG levels. Therefore, it is possible that hypergammaglobulinemia with M protein and radiation exposure both contributed to the development of TMA.
